Sitarz R, Skierucha M, Mielko J, Offerhaus JA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239–48.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209.
De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol. 2014;15:23–34.
Ren G, Cai R, Zhang WJ, et al. Prediction of risk factors for lymph node metastasis in early gastric cancer [J]. World J Gastroenterol. 2013;19(20):3096–107.
Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, et al. Gastric Cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14:1286–312.
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75.
Wang Y, Zhang J, Guo S, Meng XY, Zheng ZC, Zhao Y. Indications of neoadjuvant chemotherapy for locally advanced gastric Cancer patients based on pre-treatment clinicalpathological and laboratory parameters. J Cancer. 2020;11(20):6000–8.
Chen Y, Xiao J, Chen X, Wang H, Liu D, Xiang J, et al. Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer. World J Gastroenterol. 2020;26(19):2427–39.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology - gastric cancer: Gastric Cancer (2021.V1) [EB/OL] [2021- 03 -03]. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx#gastric.
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018. Gastric Cancer. 2021;24(1):1–21. https://doi.org/10.1007/s10120-020-01042-y.
Reddavid R, Sofia S, Chiaro P, Colli F, Trapani R, Esposito L, et al. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? World J Gastroenterol. 2018;24(2):274–89.
Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229:303–8.
Achilli P, De Martini P, Ceresoli M, Mari GM, Costanzi A, Maggioni D, et al. Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study. J Gastrointest Oncol. 2017;8:1018–25.
Lorenzen S, Thuss-Patience P, Al-Batran SE, Lordick F, Haller B, Schuster T, et al. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol. 2013;24:2068–73.
Lai J, Pan Z, Chen P, Ye G, Chen K, Su F. Development and validation of a nomogram incorporating axillary lymph node ratio to predict survival in node-positive breast cancer patients after neoadjuvant chemotherapy. Jpn J Clin Oncol. 2019;49(1):22–8.
Lai J, Wang H, Peng J, Chen P, Pan Z. Establishment and external validation of a prognostic model for predicting disease-free survival and risk stratification in breast cancer patients treated with neoadjuvant chemotherapy. Cancer Manag Res. 2018;10:2347–56.
Kim CH, Yeom SS, Lee SY, Kim HR, Kim YJ, Lee KH, et al. Prognostic impact of Perineural invasion in rectal Cancer after Neoadjuvant Chemoradiotherapy. World J Surg. 2019;43:260–72.
Tan W, Yang M, Yang H, Zhou F, Shen W. Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. Cancer Manag Res. 2018;10:4333–47.
Zhu YL, Sun YK, Xue XM, Yue JY, Yang L, Xue LY. Unnecessity of lymph node regression evaluation for predicting gastric adenocarcinoma outcome after neoadjuvant chemotherapy. World J Gastrointest Oncol. 2019;11:48–58.
Therasse P，Arbuck SG，Eisenhauer EA，et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States，National Cancer Institute of Canada J Natl Cancer Inst，2000，92(3):205–216.
Liu X, Cai H, Sheng W, et al. microRNAs expression profile re- lated with response to preoperative radiochemotherapy in patients with locally advanced gastric cancer [J]. BMC Cancer. 2018;18(1):1048.
Crookes P，Leichman CG，Leichman L，et al. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy:a fifi nal report [J]. Cancer，1997，79(9):1767–1775.
Lowy AM, Mansfifield PF, Leach SD, et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer [J]. Ann Surg. 1999;229(3):303–8.
Zhou J, Shen J, Seifer BJ, et al. Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer [ J]. Oncotarget. 2017;8(18):30477–94.
Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with Para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653–60.
Ito S, Sano T, Mizusawa J, Takahari D, Katayama H, Katai H, et al. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus Para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer. 2017;20:322–31.
Iwasaki Y, Sasako M, Yamamoto S, Nakamura K, Sano T, Katai H, et al. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol. 2013;107:741–5.
Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol. 2012;19:2119–27.
Li ZY, Koh CE, Bu ZD, Wu AW, Zhang LH, Wu XJ, et al. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. J Surg Oncol. 2012;105:793–9.
Sorensen LT, Nielsen HB, Kharazmi A, Gottrup F. Effect of smoking and abstention on oxidative burst and reactivity of neutrophils and monocytes. Surgery. 2004;136(5):1047–53.
Kelemen L, Warren G, Koziak J, Köbel M, Steed H. Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer. Gynecol Oncol. 2016;140(1):124–30.
He T, Hu J, Qiu D, Deng H, Hu J, Chen J, et al. Smoking status and pathological response to neoadjuvant chemotherapy among patients with bladder cancer: a pooled analysis. Translational andrology and urology. 2021;10(1):374–83.
Boeri L, Soligo M, Frank I, Boorjian S, Thompson R, Tollefson M, et al. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-Centre experience. BJU Int. 2019;123(6):1011–9.
Kuol N, Stojanovska L, Apostolopoulos V, et al. Crosstalk between cancer and the neuroimmune system [J]. J Neuroimmunol. 2018;315:15–23.
Huong PT, Nguyen LT, Nguyen XB, et al. The role of platelets in the tumor-microenvironment and the drug resistance of cancer cells [J]. Cancers (Basel). 2019;11(2). https://doi.org/10.3390/cancers1102.
Haemmerle M, Stone RL, Menter DG, et al. The platelet lifeline to cancer: challenges and opportunities [J]. Cancer Cell. 2018;33(6):965–83. https://doi.org/10.1016/j.ccell.2018.03.002.
Felix K, Gaida M. Neutrophil-derived proteases in the microenvironment of pancreatic Cancer -active players in tumor progression. Int J Biol Sci. 2016;12(3):302–13.
Sano T, Coit D, Kim H, Roviello F, Kassab P, Wittekind C, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: international gastric Cancer association staging project. Gastric Cancer. 2017;20(2):217–25.
Pelc Z, Skórzewska M, Rawicz-Pruszyński K. Lymph node involvement in advanced gastric Cancer in the era of multimodal treatment—oncological and surgical perspective. Cancers (Basel). 2021;13(10):2509.
Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocar cinoma (FLOT4): a randomised, phase2/3 trial. Lancet. 2019;393:1948–57.
Armstrong D, Raissouni S, Price Hiller J, Mercer J, Powell E, MacLean A, et al. Predictors of pathologic complete response after Neoadjuvant treatment for rectal Cancer: a multicenter study. Clin Colorectal Cancer. 2015;14:291–5.
Chen S, Chen YB, Li YF, Feng XY, Zhou ZW, Yuan XH, et al. Normal carcinoembryonic antigen indicates benefit from perioperative chemotherapy to gastric carcinoma patients. World J Gastroenterol. 2012;18:3910–6.
Wallin U, Rothenberger D, Lowry A, Luepker R, Mellgren A. CEA -a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer. Dis Colon Rectum. 2013;56:859–68.
Probst CP, Becerra AZ, Aquina CT, Tejani MA, Hensley BJ, González MG, et al. Watch and wait?Elevated pretreatment CEA is associated with decreased pathological complete response in rectal Cancer. J Gastrointest Surg. 2016;20:43–52.
Ji X, Yang Q, Qin H, Zhou J, Liu W. Tumor blood supply may predict neoadjuvant chemotherapy response and survival in patients with gastric cancer. J Int Med Res. 2019;47:2524–32.
Xu XR, Zhang D, Oswald BE, et al. Platelets are versatile cells: new discoveries in hemostasis,thrombosis,immune responses, tumor metastasis and beyond [J]. Crit Rev Clin Lab Sci. 2016;53(6):409–30. https://doi.org/10.1080/10408363.2016.1200008.